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Peripheral blood mononuclear cell secretome for tissue repair
Lucian Beer1,2 · Michael Mildner4 · Mariann Gyö gyösi5 · Hendrik Jan Ankersmit2,3,6
stroke, and wound healing. In this review we describe the 
benefits of choosing PBMCs instead of stem cells in regen-
erative medicine and characterize the factors released from 
apoptotic PBMCs. We also discuss pre-clinical studies 
with apoptotic cell-based therapies and regulatory issues 
that have to be considered when conducting clinical tri-
als using cell secretome-based products. This should allow 
the reader to envision PBMC secretome-based therapies as 
alternatives to all other forms of cell-based therapies.
Keywords PBMC  · Regenerative medicine ·  
Tissue regeneration · Paracr ne · Secretome
Introduction
The concept of using paracrine factors in a therapeutic con-
text in regenerative medicine can be seen as a consequence 
of the stem cell theory in the beginning of the twenty-first 
century. Here we will discuss the beginnings of stem cell 
research, with its promising initial results and subsequent 
disillusion, followed by the development of the secretome 
concept in regenerative medicine. We will discuss the term 
“secretome”, char cterize the components of the cell secre-
tome, describe its effects in pre-clinical and clinical studies, 
and then ou line the challenges and opportunities of secre-
tome-based therapies in regenerative medicine.
Development of the paracrine/secretome 
hypothesis
The origin of modern cell-free therapies can be traced back 
to the late ninete nth and early twentieth centuries. The 
Swiss physician Paul Niehans (1882–1971) coined the term 
Abstract For almost two decades, cell-b sed therapies 
have been tested in modern r generative medicine to either 
replace or regenerate human cells, tissues, or organs and 
restore normal function. Secreted paracrine factors are 
increasingly accepted to exert beneficial biological effects 
that promote tissue regeneration. These fa tors a  called 
the cell secretome and include a variety of proteins, lipids, 
microRNAs, and extracellular vesicles, such as exosomes 
and microparticles. The stem c ll secretome has most c m-
monly been investigated in pre-clinical settings. However, 
a growing body of evidence indicates that other cell types, 
such as peripheral blood monon clear c lls (PBMCs), are 
capable of releasing significant amounts of biologically 
active paracrine factors that exert beneficial regenerative 
effects. The apoptotic PBMC secretome has been success-
fully used pre-clinically for the treatment of acute myo-
cardial infarction, chronic heart failure, spinal co d injury, 
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myocardial infarction in athymic rats (impaired immune 
system) when injected intravenously 48 h after vascular 
ligation [10]. Orlic et al. showed that intramyocardial injec-
tion of murine c-KIT+ bone marrow-derived cells in mice 
improves hemodynamic functions; the authors claimed that 
these stem cells enhanced myocardial regeneration by de 
novo generation of functional myocardium [11].
Based on these encouraging pre-clinical experiments, 
several groups rapidly transferred the “stem cell potential” 
to the realm of clinical application. Initial trials, such as the 
randomized controlled trial TOPCARE-AMI, were able to 
show minor improvements in left ventricular function fol-
lowing intracoronary injection of autologous progenitor 
cells [12]. However, ambiguous results were published in 
subsequent years without providing evidence that a single-
cell-based therapy has significant effectiveness [13]. How-
ever, three recent meta-analyses generated contradictory 
results. Fisher et al. reported that autologous cell therapy 
may reduce the risk of mortality and re-hospitalization in 
patients with HF [14, 15]. Gyöngyösi et al. showed that 
intracoronary stem cell therapy following AMI provides no 
clinical benefits or reduction in mortality [16]. Gyöngyösi 
et al. performed an individual participant data (IPD)-based 
meta-analysis consisting of 12 randomized controlled trials 
with 1252 patients and concluded that neither clinical data 
nor left ventricular functions were significantly improved 
by intracoronary cell therapy following AMI [16]. These 
data highlight the lack of clinical efficacy of stem cell ther-
apy in the clinical setting of AMI and dampen the enthusi-
asm for resource-intensive research into cell-based therapy. 
The controversial discussion on the efficacy of stem cell 
therapy is ongoing, and the current BAMI trial funded by 
the European Commission (ClinicalTrials.gov Identifier: 
NCT01569178) will provide definitive answers in a well-
designed and controlled study.
How can we interpret the data generated during the last 
two decades in stem cell research and, more importantly, 
what lessons have been learned from these investigations? 
Given that the injection of diverse types of stem cells can 
promote cardiomyocyte cytoprotection/regeneration pre-
clinically, it was initially thought that these stem cells 
incorporate into the injured organ and transdifferentiate into 
cardiomyocytes [11]. Later, it was shown that mesenchymal 
stem cells (MSCs) not only engraft and differentiate into 
cardiomyocytes, but also stimulate the proliferation and 
differentiation of endogenous cardiac stem cells [17], and 
allogeneic MSCs stimulate the proliferation of endothelial 
progenitor cells, restoring normal endothelial function [18].
In contrast, only a small percentage of injected stem 
cells engraft in the heart [19]. Penicka et al. reported that 
approximately 5 and 1 % of stem cells remain in the human 
myocardium 2 and 18 h after intracoronary infusion, respec-
tively [20, 21]. The vast majority of cells were sequestered 
“cell therapy”. His cell therapy patients included celebr-
ties such as Winston Churchill, Pope Pius XII, Agha Kahn, 
and Charles de Gaulle. Niehans exte sively evaluated the 
effects of endogene rejuvenation via jection f xenoge-
neic cell suspensions derived from the endocrine glands, 
heart, kidney, liver, bone marrow, intestinal mucosa, and 
reticulo-endothelial system into the corresponding organ, 
studying whether normal function was restored. He also 
studied blood enriched with l ukocytes and hypothesized 
that this form of treatmen  could be used for a myriad of 
degenerative diseases and c cer. Niehans used ither fresh 
xenogeneic cells in suspen i n or lyophiliz d xenogeneic 
cells (vacuum freeze-dried) derived f om y ung animals, 
such as sheep or animal fetuse , or human fetal cells [1]. 
Based on his experience with 3000 treated patien s, Niehans 
postulated that xenogeneic cell infu io was well tolerated 
and not associated with any adverse reaction. Interestingly, 
as early as 1954, Rietschel and Pischinger articu ated their
reservations regarding the implantation of xen geneic cells 
based on their data that xenograf  transplantation induces a 
xenogeneic immune response, as well as the risk of rans-
mitting zoonosis [2, 3].
Prior to Niehans, physicians experiment with stem 
cell-like cell types, including Alexander Mak mov in 1909 
during his work on blood formation [4]. I  addition, E ie 
Metchnikoff, and later Alexander Bogomolets, worked on 
the development of an adjuvant immunothe apy consist-
ing of cytotoxic sera thought to prolo g life and attenuate 
chronic diseases [5]. However, efficacy has not been sys-
tematically demonstrated, though these researchers were 
enthusiastic proponents of thei  own theories and treat-
ment options. By modern standards, their results never 
progressed beyond an exper  opinion and the publication of 
case reports. The lack of well-conducted studies in the field 
of “cell therapies” was the cause of well-argued skepticism 
throughout the twentieth century.
The current concept of using autologous or allogeneic 
stem cells for replacing or engin eri g injured tissues to e-
establish normal biological function was re-envisi ne  in 
the beginning of the twenty-first century in the clinical set-
ting of acute myocardial infarction (AMI) and chronic heart 
failure (HF). Initially, it was thought that the human heart is 
a post-mitotic and terminally evel ped o gan ith n  cell 
renewal capacity, but this dog a was refuted in 2001 when 
enhanced myocyte cell proliferation was demonstrated fol-
lowing AMI [6] and then confirmed by other groups [7, 8]. 
Further studies revealed th t a small number of extra-car-
diac progenitor cells are capable of migrating into the da -
aged human myocardium following heart tra spl ntation to 
replace damaged cardiomyocytes [9]. A variety of pre-clin-
ical studies simultaneously showed s riking resu ts by using
different sources of stem cells for the treatment of acute 
AMI. Human bone marrow-derived CD34-cells attenuated 
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mediators, such as IL-1β, IL-8, and TNF-α were inhibited 
[35]. However, Thum et al. not only hypothesized that bene-
ficial local immune reactions are induced by apoptotic stem 
cells, but also speculated that any other nucleated cell type 
undergoing programmed cell death may improve myocar-
dial regeneration.
Proof and extension of Thum’s apoptosis 
hypothesis
Thum’s hypothesis was proven by Ankersmit et al., who 
sought to answer two major questions using a wild-type 
rodent model of acute AMI: are PBMCs capable of attenu-
ating myocardial damage when injected intravenously after 
coronary ligation and does the induction of apoptosis in 
PBMCs prior to injection alter their biological activity?
Using in vitro assays, Ankersmit et al. were able to show 
that gamma-irradiated apoptotic PBMCs attenuated lipo-
polysaccharide (LPS)-induced spillage of IL-6 and IL-1β in 
co-cultured monocytes and PBMCs [36]. In addition, irradi-
ated PBMCs reduced T-cell proliferation in mixed lympho-
cyte reaction assays [36].
In in vivo experiments using a rodent model of acute 
AMI induced by ligation of the left anterior descending 
artery (LAD), the infusion of irradiated PBMC suspensions 
(apoptotic PBMC-S) reduced infarct size compared to ani-
mals receiving non-irradiated PBMCs (living PBMC-S) or 
cell culture medium alone. Functional parameters (ejection 
fraction, end-systolic and end-diastolic diameters) were 
improved in animals treated with apoptotic PBMC-S [36]. 
In line with these findings, qualitative and quantitative 
changes were observed in myocardial cell infiltrates 72 h 
after AMI in rats receiving apoptotic PBMC-S. In contrast, 
rats receiving non-irradiated PBMCs or control media had a 
mixed cellular infiltrate in the border zone (e.g., fibroblasts, 
neutrophils, lymphomononuclear cells, macrophages/
monocytes, endothelial cells, and dystrophic cardiomyo-
cytes), and rats treated with irradiated PBMCs had a mas-
sive infiltration of CD68+ mononuclear cells (monocytes/
macrophages). These animals also had cells positive for 
c-KIT+ (CD117) and vascular endothelia growth factor 
receptor 2 (VEGF-R2) [36]. Ankersmit et al. also tested 
whether conditioned medium from apoptotic PMBCs may 
influence gene expression by fibroblasts and keratinocytes 
in vitro. Surprisingly, the co-incubation of human primary 
fibroblasts and keratinocytes with paracrine factors derived 
from apoptotic PBMCs induced a massive upregulation 
of MMP-9, VEGF, and IL-8. Thus, this study showed that 
apoptotic PBMC secretome exerts anti-inflammatory effects 
and reduce myocardial injury following AMI, and that the 
supernatants from these cells induce the expression of pro-
angiogenic genes in vitro. Looking at the condition media 
in the spleen, liver, lung, bone marrow, an  lymph nodes a 
few hours after infusion [21, 22]. Subsequent studies could 
not reproduce the stem cell different ation into ardiac cells. 
Specifically, c-KIT+ cardiac progenitor cells [23] were 
unable to differentiate into ca diomyocytes or support myo-
cardial regeneration follow ng myocardial infarction. Murry 
et al. failed to identify any transdifferentiation of hemato-
poietic stem cells into cardiomyocytes in 145 transplants 
into normal and injured adult mouse h arts [24].
If stem cells do not engraft in a biologically relevant 
manner or demonstrate long-term survival in injured heart 
[25], how can we explain the beneficial effects? Recent evi-
dence suggests that, instead of direct cell fusion or tran d f-
ferentiation, paracrine factors released by injected cell are 
responsible for the beneficial effects. Gnecchi, using in vivo 
data, was one of the first to propose that infused stem cells 
may exert their biological effects via the secretion of para-
crine factors in addition to cell–cell interactions. In 2005, 
this group reported that conditioned medium from MSCs 
under hypoxic stress significantly attenuated hypoxia-
induced cell death among adult rat ventricular c r iomyo-
cytes [26]. Gnecchi and Dzau demonstrated the importance 
of paracrine factors derived from stem cells in tissue regen-
eration in several studies and reviews [27–30]. Another pio-
neer in the field is Prof. Dr. KC Wollert, who speculated in 
2005 about the role of paracrin  factors from stem cells in 
regenerative medicine [31]. Interestingly, in 2008 the same 
group showed that supernatants obtained from PBMCs have 
only marginal differences from the ste  cell secr tome 
regarding the ability to promote cell proliferatio . In ad -
tion, ProteinChip and GeneChip analysis of paracrine fac-
tors revealed minor differences [32], supporting he study 
of alternative mechanisms u derlying nu leated stem cell 
therapy in the field of regenerative medicine.
Death of the stem cell hypothesis
Cell necrosis-induced inflammatory reactions are an integral 
part of the pathophysiology of my cardial ischemia. The e 
inflammatory processes augment cardiomyocyte dysfunc-
tion and ventricular remodeling. In 2005, Thum et al. pro-
posed that immunomodulatory signals released by injected
apoptotic stem cells may be responsible for the beneficial 
effects observed in the initial clin cal tri ls utilizing ex vivo 
manipulated stem cells [33]. They drew attention to the 
fact that 5–25 % of all injected stem cells re apo totic [34] 
and proposed that these dying cells attenuate inflammatory 
reactions via the induction of anti-inflammatory cytokines 
(e.g., TGF-β, IL-10) by macrophages. This hypothesis was 
supported by the observation that apoptotic neutrophils aug-
ment TGF-β, prostaglandin E2 (PGE2), and platelet activa-
tion factor expression in phagocytes, whereas inflammatory 
1 3
1339Apoptosis (2016) 21:1336–1353
survival, such as nanovesicles [58], lipids [59], exosomes, 
and proteins [60].
Pre-clinical application of nucleated apoptotic cells
Based on the immunomodulatory capacities of apoptotic 
cells during the last decade, several pre-clinical studies 
evaluated their usage for the treatment of autoimmune dis-
ease or organ transplantation (Table 1) (reviewed i [52]).
Gray et al. reported that the infusion of apoptotic thymo-
cytes attenuated the severity or prevented the development 
of collagen-induced arthritis in mice via the modulation 
of regulatory B cells and CD4+ T-cells [55]. Perruche et 
al. published comparable results using streptococcal cell 
wall-induced arthritis in rats. The intraperitoneal injection 
of gamma-irradiated apoptotic thymocytes at the time of 
immunization reduced disease severity [53]. In a murine 
model of methylated BSA-induced arthritis, the application 
of etoposide induced apoptotic dendritic cells, but LPS-
activated apoptotic dendritic cells inhibited arthritis [90]. In 
addition, Grau et al. used an autoimmune mediated colitis 
model to evaluate the effect of gamma-irradiated apoptotic 
splenocytes or human apoptotic mononuclear cells. The 
authors were able to show that apoptotic cells attenuated 
pro-inflammatory cytokine release from macrophages and 
the severity of colitis [67]. Several groups have investigated 
the effects of injecting apoptotic cells in the transplant set-
ting. The injection of apoptotic splenocytes has been shown 
to attenuate acute cardiac allograft rejection in rats [77] and 
mice [91] and ameliorate chronic allograft vasculopathy in 
mice [80]. In addition, gamma-irradiated splenocytes pro-
mote allogeneic bone marrow engraftment [83, 84, 92]. The 
infusion of apoptotic leukocytes 7 days before the admin-
istration of allogeneic pancreatic islets has been shown to 
improve transplant survival through the modulation of regu-
latory T-cells [81].
Similarly, Perotti et al. performed a clinical case study of 
the use of allogeneic gamma-irradiated cord blood mononu-
clear cells in a patient with critical limb ischemia, reporting 
improved wound closure and vascularity [93]. Holzinger et 
al. chose an alternative approach; they harvested autologous 
PBMCs from diabetic patients with venous foot ulcers and 
stimulated them ex vivo with phytohemagglutinin. They 
then applied these cell suspensions to the foot ulcers. The 
clinical effect was significant enhancement of granulation 
and epithelialization of the skin ulcers [94].
In an unrecognized citation, in 1970 Földes et al. inves-
tigated whether the injection of anti-lymphocyte serum, 
which induces apoptosis in PBMCs in vivo and vitro [95], 
is able to attenuate experimental AMI [89]. In their historic 
work, they were able to show that the injection of anti-lym-
phocyte serum immediately decreased ischemic myocardial 
data, it was obvious to us that the secretome of nucleated 
apoptotic PBMCs is the only explanation and easily obtain-
able solution in regenerative medicine.
Apoptosis and the rise of the Phoenix signaling 
pathway
At first glance, the statement “Dying cells can augment 
cell survival” seems contradictory, but afte  detailed con-
sideration has an evolutionary justification and rationale. 
Apoptosis (Greek: apo = off, away + ptosis = a falling) 
was coined in 1972 [37] to represent n actively enforced 
process during normal development and morphogenesis 
throughout a lifetime with characteristic mo phologica  
changes [38]. Apoptosis is an ctively xecuted process nd 
highly diverse between different tissues. To illus rate e 
magnitude of apoptosis as a physiological process aiming 
to maintain constant cellular sel -r newal and homeostasis, 
every day 1 × 1011 human neutrophils underg  apoptosis 
[39] and every second approximately 3000 ery hrocytes 
enter the apoptotic pathway and are degraded in the reti-
culo-endoplasmic system in th  spleen and liv r or are 
phagocytosed by macrophage  [40]. Up to 95 % of all thy-
mocytes descending in the thymus ar  negatively selected
and undergo programmed cell de th to r move autoimmune 
T-cells [41]. Even organs with low cellular turnover, such 
as the brain, discard 50 % of all cells during morphogenesis 
[42].
Defects during these physiological processes cause 
autoimmune diseases or macular degeneration in the eye 
[43]. Apoptotic lymphocytes are known to play important 
roles in the pathophysiology of several chronic inflamma-
tory diseases and are elevated f ll wing implantation of 
left-ventricular assistance devices [44] or heart transplan a-
tion [45] and during hemodialysis [46, 47], s psis [48–50], 
COPD, and asthma (reviewed in [51]). Thus, from this his-
toric data set multiple pathologica  disease en ities related to 
augmented initiation of apoptosis in PBMCs in the immune 
system can be deduced.
Apoptotic cells exert immunom dulat ry effects either 
by releasing active immune mediators directly or indirectly 
via the modulation of phagocytes an  dendritic c ll [52]. 
The infusion of apoptotic cells tenuates systemic con-
centrations of inflammatory cytokines [53, 54], whereas 
anti-inflammatory cytokines, such as IL-10 [55–57] and/or
TGF-β [53, 57], are released.
Apoptotic cells can also actively support regenerative 
and cytoprotective pathways. Figuratively speaking, he 
apoptotic cells alert surrounding cell of danger a d help 
protect and survive by entering the proc ss of programmed 
cell death in a kamikaze-like mission. Apoptotic cells 
release growth signals that stimulate cell proliferation nd 
1 3














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pigs receiving apoptotic cell secretome had an ejection 
fraction (57.0 versus 40.5 %), improved cardiac output (4.0 
versus 2.4 L/min), and reduced infarct area (12.6 versus 
6.9 %) compared to controls (see Table 2). Lichtenauer et al. 
showed that cardiomyocytes exposed to apoptotic PBMC-
S increased pro-survival proteins (AKT, ERK1/2, CREB, 
c-Jun) and anti-apoptotic genes (Bcl-2, BAG1), and pre-
vented starvation-induced cell death in primary cultured 
human cardiomyocytes. These in vitro data indicated that 
apoptotic PBMC-S enhances endogenous myocardial pro-
tection and repair following AMI [97]. The production pro-
cess of these paracrine factors is illustrated in Fig. 1.
Hoetzenecker et al. showed that, in addition to an effect 
on intracellular myocardial signaling cascades, apoptotic 
PBMC-S preserved porcine epi/myocardial microvascular 
perfusion in a closed chest reperfusion infarction model 
[99]. Microvascular obstruction was measured by functional 
magnetic resonance imaging (fMRI) and cardiac catheter-
ization in treated animals. Both methods revealed improved 
microvascular blood flow in treated animals. In addition, 
apoptotic PBMC-S induced up-regulation of eNOS, iNOS 
in cultured HUVECs, and vasodilator-stimulated phos-
phoprotein (VASP) activation in platelets [99]. These data 
indicate that apoptotic PBMC-S not only caused direct cyto-
protective effects in injured hearts, but also induced sys-
temic effects on circulating platelets and endothelial cells.
This work was extended by Pavo et al., who were able 
to demonstrate that apoptotic PBMC-S exerts regenerative 
effects in a latent porcine chronic post-myocardial infarc-
tion model [102]. In these experiments, pigs were subjected 
to a 90-min occlusion followed by reperfusion of the mid-
left ventricular descending coronary artery. 30 days later, 
the animals received either apoptotic PBMC-S or control 
medium in the border zone after myocardial infarction via a 
NOGA catheter. On day 60, they were able to show that sec-
retome-treated animals had a significantly reduced infarct 
size and improved cardiac index compared to controls. 
Transcriptional gene analysis of the myocardium revealed 
higher expression of protective myogenic factor Mefc2 and 
reduced expression of pro-apoptotic genes in treated pigs 
[102]. These data led the authors to conclude that apop-
totic PBMC-S promotes curative gene signatures as late as 
30 days after the application of PBMC-S in animals with 
chronic ischemic left ventricular dysfunction.
The pathophysiology and molecular processes follow-
ing ischemic stroke are somewhat similar to those of AMI. 
Following vascular obstruction due to a ruptured athero-
sclerotic plaque or arterial thrombus, the downstream cells 
become hypoxic and eventually apoptotic/necrotic. As 
in myocardial infarction, immediate restoration of blood 
flow is the first line treatment in patients with acute isch-
emic stroke. Altmann et al. showed that, in a rodent model 
of cerebral stroke, the administration of apoptotic cell 
damage and arrhythmia in experim ntal AMI. They a trib-
uted these effects to the immunosuppress ve effects of the 
anti-lymphocyte serum. This therapy concept was con-
firmed and extended by Lichtenauer et al. [88]. Lichtenauer 
et al. injected the commercially available m unosuppres-
sive agent rabbit ATG (rATG, Thymoglobulin, Genzyme, 
Germany) into rodents exposed to permanent LAD ligation 
[88]. rATG is a successfully applied drug in cl ical trans-
plant immunology that has a mechanism comparable to anti-
lymphocyte serum. Experimental in vivo ATG treatment 
reduced the area of necrosis and improved myocardial func-
tion compared to control treatment. In vitro data confirmed 
that ATG induced the release of several pro-angiogenic 
proteins from rat and human PBMCs into the supernatant, 
such as CXLC8 (IL-8). Furthermore, these pa acrine factors 
induced the down-regulation of p53 i  cultured human car-
diomyocytes, suggesting a direct ytoprotective effect. The 
authors concluded that, in vivo, ATG induces the apoptosis 
of lymphocytes, which release paracrine f ctors th t reduce 
ventricular remodeling and mprove cardiac funct n after 
experimental AMI [88]. Relevant to th s hypothesis is a case 
report published in 2006, wherein a patient with giant cell 
myocarditis (GCM), a rare and fatal disorder, presented with 
ventricular arrhythmia and congestive HF with he primary 
misdiagnosis of myocardial infarction. This patient was 
saved by extracorporeal membrane oxygenation (ECMO) 
and concomitant application of rATG (Thymoglobuline, 
Sangstat) after histological proof of GCM. This was the first 
report in the literature of complete remission in this fatal 
disease and was the inspirational nidus and implicit valida-
tion for studying apoptotic PBMCs and c nditioned media 
(i.e., PBMC-S) in experimental myocarditis and other indi-
cations [96].
Thus, most of these studies njected apoptotic spleno-
cytes or thymocytes, and only two studies induced leuko-
cyte apoptosis in vivo. The proposed mechanisms for these 
cell-based therapies include immunomodulatory effects 
induced by the clearance of apoptotic cells by phagocytes 
and characterized by the direct r lease of immunosuppres-
sive factors (e.g., IL-10, TGF-β) [52]. Whether the inj ction 
of nucleated cells or their released factors is sufficient to 
induce the immunomodulatory systemic eac ions h s not 
yet been studied.
Paradigm changes in tissue repair—validation of 
the PBMC secretome
Initially, Ankersmit’s group was able to show that the injec-
tion of paracrine factors released from apopto c PBMCs 
attenuates myocardial damage and pr s rves myocardial 
function following AMI in a wild type rodent model and 
clinically more relevant p rcine large animal model [97]. 
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barrier dysfunction [106]. Haider et al. investigated the 
role of the apoptotic cell secretome in a rodent spinal 
cord injury model [104]. Rats treated with paracrine fac-
tors from irradiated PBMCs had significantly improved 
neurological function compared to the control group. His-
tological evaluation of spine sections revealed a smaller 
spinal cord cavity, reduced axonal damage, and improved 
vascularity index around the lesion. The PBMC secretome 
enhanced angiogenesis in aortic ring assays and spinal 
cord tissue. The authors also tested whether an immuno-
logical mechanism may be involved in neuroprotection. 
The secretome-treated animals exhibited enhanced recruit-
ment of CD68-positive cells with parallel reduction in the 
levels of iNOS 3 days after injury. These data indicate that 
the PBMC secretome increases the presence of cells with 
known beneficial anti-inflammatory effects after spinal 
cord injury that accelerate the clearance of immunologi-
cal disturbances, attenuating the secondary damage after 
spinal cord injury [104].
The PBMC secretome has been shown to enhance wound 
healing in vivo and in vitro [101, 105]. Mice with artificial 
secretome reduced the ischemic area by 36 % and improved 
the functional neurological outcome [103]. In vitro assays 
revealed enhanced sprouting of human neurons and the up-
regulation of pro-survival pr teins (CREP, ERK1/2, c-Jun, 
Hsp27) in primary cultured astrocytes and Schwann cells. 
Interestingly, the intraperit neal applic  human 
apoptotic PBMC-S in naïve rodents massively increased the 
secretion of rat brain-deri ed neu o rophic f ctor (BDNF), a 
neuroprotective peptide alluded to neurogenesis. These data
further support apoptotic PBMC-S having not only direct 
regenerative/cytoprotective effects on injured organs, but 
also systemic effects, overcoming tissue damage d cell 
death in the acute phase of hypoxia.
Similar to stroke, the neurological damage following 
acute spinal cord injury initiates a short initial trauma 
followed by a second injury caused by the endogenous 
immune response to the traumat c injury. This s cond
undesirable phase of spinal cord injury consis s of a mul-
tilayered and complex combination of inflammatory path-
ways that are thought to drive ongoing issue damage via 
enzymatic degradation, oxidative stress, and blood–brain 
Table 2 Pre-clinical and clinical application of apoptotic PBMC-S
SpeciesExperimen-
tal model





Rat AMI Reduced infarct size, 
improved functional 
parameters
i.v. 25 × 106 Syngen γ-irradiation 
(60 Gy)
[98]
Pig AMI i.v. 25 × 106 Syngen γ-irradiation 
(60 Gy)
[97]
Pig AMI i.v. 25 × 106 Syngen γ-irradiation 
(60 Gy)
[99]
Mice EAM Resolution of acute 
inflammation







Topical 25 × 106 Syngen γ-irradiation 
(60 Gy)
[101]
Pig Chronic HFImproved functional 
parameters
i.m. 25 × 106 Syngen γ-irradiation 
(60 Gy)
[102]
Rat StrokeReduced infarct size, 
improved neurologi-
cal parameters







Rat SCI Reduced trauma size, 
improved neurologi-
cal parameters









Topical 25 × 106 Human γ-irradiation 
(60 Gy)
[105]
Pig AMI Reduced infarct size, 
improved functional 
parameters














AMI acute myocardial infarction, EAM experimental autoimmune myocarditis, HF heart failu e, SCI spinal cord injury, i.v. intravenous, i.p. 




infiltrate, offering a novel treatment option in an experimen-
tal myocarditis model. The authors showed that PBMC-S 
induced caspse-8-dependent apoptosis of autoreactive CD-
4-positive T-cells, leading to remission of the decorative 
autoimmune processes [100] in a well-defined myocarditis 
model.
The immunomodulatory effects of PBMC-S were further 
evaluated by Kasiri et al. [107]. In this study the authors 
were able to show that PBMC-S contains significant 
amounts of antimicrobial peptides. In vitro experiments 
revealed antimicrobial activity against Gram-negative bac-
teria and Gram-positive bacteria. In addition, intravenous 
application of apoptotic PBMC-S in rats increased de novo 
endogenous AMP production in vivo. The authors deduced 
that PBMC-S has direct and indirect positive effects on the 
immune system.
Based on these data, we concluded that apoptotic PBMC-
S initiates multiple modes of action (MOAs) that eventually 
dermal wounds were treated with mulsion c ntaining either 
PBMC secretome or control medium. 6 d ys after injury, 
wound closure was significantly enhanced in secretome-
treated animals compared to con rol animals. Histologi-
cal evaluation showed accelerated r -epithelializat on a  
neo-angiogenesis. In line with these in vivo data, experi-
ments with keratinocytes and fibroblasts showed enhanced 
proliferation and up-regulation of pro-survival signaling 
pathways after co-incubation with PBMC secret me [101]. 
In a clinically relevant pig skin burn model, Hacker et al. 
reported that PBMC secretome accelerated wound quality, 
augmented neo-angiogenesis, and decreased the number of 
mast cells [105].
Recently, Hoetzenecker et al. investigated the capacity 
of apoptotic PBMC-S to modulate myocardial inflamma-
tion in a CD4-positive T-cell-dependent murine model of 
autoimmune myocarditis. Mice receiving apoptotic PBMC–
S at the clinical onset of disease had reduced lymphocyti  
Fig. 1 Schematic workflow of the preparation of apoptotic PBMC 
secretome. PBMC-enriched blood bags are obtained by blood banks 
and used for the generation of paracrine factors. The PBMCs are fur-
ther purified using Ficoll-paque centrifugation. Apoptosis is induced 
by 60 Gy gamma-irradiation. The PBMCs are then cultivated at 37 °  
in 5 % CO/5 % CO2 for 24 h. The cells are removed by centrifugation 
and ultrafiltration. The remaining cell culture supernatant containing 
the paracrine factors is subjected to methylene blue viral clearance. 
The viral cleared supernat nt is then lyophilized to remove all soluble 
factors. The remaining solid compartments are subjected to a second 
viral clearance step and irradiated with 30k Gy, eventually yielding the 
final pr duct produced in accordance with GMP
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surface markers. Particles with a diameter of 100–1000 nm
are called microvesicles (MV) or microparticles, whereas 
particles with a diameter <100 nm are called exosomes 
(reviewed in [112]). MVs originate from plasma membrane 
shedding and contain high amounts of phosphatidylserine, 
selectin, integrin, and CD40. In contrast, exosomes are gen-
erated intracellularly and stored in the multivesicular bodies 
until fusion with the plasma membrane and exocytosis of 
the vesicles. Almost all cell types, including immune cells 
[113], cancer cells [114], and stem cells [115], are capable 
of releasing exosomes. Importantly, exosomes contain a set 
of proteins, lipids, messenger RNA (mRNA), and micro 
RNA (miRNA) that is distinct to the cytosolic compartment 
responsible for intercellular signaling [112].
Using both ultracentrifugation and a magnetic bead-based 
protocol, Beer et al. characterized exosomes and micropar-
ticles of irradiated and non-irradiated PBMCs. Gamma-irra-
diation induced the release of exosomes and microparticles 
and altered the exosomal protein content. Functional analy-
sis revealed that exosomes and proteins are the two major 
biological components that induce keratinocyte and fibro-
blast migration and the secretion of pro-angiogenic proteins.
Although the principle components released from apop-
totic PBMCs have been characterized, there are questions 
yet to answer. What is the biologically active component? 
Which factors interact with each other, whose separation 
would abolish the biological activity. Based on the com-
plexity of pathological changes during an ischemic injury, it 
seems rather plausible to target variable pathological path-
ways using multifaceted drug compounds, such as apoptotic 
PBMC-S, instead of focusing on one single aspect. The 
identification of a specific cause and effect relationship on 
a cellular level is a matter of systems biology rather than 
to define a drug compound that is potentially able to treat 
multiple indications of unmet need.
From bench to bedside—the potential benefit and 
safety of secretome-based therapy
Basic science and pre-clinical research should ultimately 
aim to transfer knowledge into clinical practice. Though 
stem cell-based clinical trials at the beginning of the twen-
tieth century have paved the way for regenerative medicine, 
the first clinical trials utilizing the PBMC secretome will 
successfully provide proof-of-concept in humans for sev-
eral indications with unmet need. Diabetic foot ulcer, AMI, 
stroke, and spinal cord injury are the first such indications. 
Ankersmit’s group recently finished a phase I study utilizing 
autologous GMP PBMC secretome (“Marsyas 1”, EudraCT 
Nr.: 2013-000756-17).
In addition to these clinically oriented issues, funda-
mental basic research has to be done in order to identify 
lead to cytoprotection and p evention of hypox  tissue in
vivo.
The quest for the biologically active ompo ent(s) 
of apoptotic PBMC secretome
A plethora of unresolved q estions are still unanswered 
regarding which component(s), con entration(s), and 
mode(s) of delivery are responsible for the effe ts of the 
PBMC secretome. A single molecule may re ulate a broad 
spectrum of different processes, including platelet inhibi-
tion, vasodilation, neo-angiogenesis, and cytoprotection.
Another option is a pleiotropy f factors alon  or in combi-
nation that orchestrate different molecular cascades, leading 
to the beneficial effects. In order to determine the MOA of 
the PBMC secretome, we first have to define the secretome 
itself.
Using a systemic approach, Beer et al. tri d to classify 
the secretome components of gamma–irradiated apoptotic 
PBMCs [108] based on their princip e molecular character-
istics in proteins (e.g., cytokines and growth factors), extra-
cellular vesicles (e.g., microparticles and exosomes), and 
lipids (Fig. 2). Lichtenauer et al. performed cytokin  mem-
brane arrays using supernatant from irradiated and non-irra-
diated PBMCs; particularly when stressed, the supernatants 
contained high amounts of chemokines (e.g., CXCL8, 
CXCL5, CXCL1, CCL5, VEGF) [97]. We also utilized a 
bioinformatics-based approach in in vitro cultured PBMCs 
and irradiated PBMCs. A total of 213 putative tively 
secreted proteins were identified in the transcriptome of 
irradiated PBMCs and 167 transcripts in non-irradiated 
PBMCs [60], highlighting that irradiation causes PBMCs to 
become a highly active “bior actor” while u derg ing pro-
grammed cell death.
A growing body of evidence indicates that lipids released 
from apoptotic cells exert paracrine biological activity [109, 
110]. Using the PBMC secretome, we focuse  on xidized 
phospholipids because this group f lipids has pleiotropic 
biological effects ranging from the induction of endothelial 
cell proliferation and angiogenes s, to the attenuation of 
Toll-like receptor (TLR)-induced inflammation and the inhi-
bition of oxidative burst in neutrophil granulo ytes. Using 
high pressure lipid chroma ography we measured increased 
concentrations of oxidized phospho ip ds in sup rnatant 
from irradiated PBMCs, especially PLPC-OOH, PAPC-
OOH, SGPC, and PGPC [60].
In addition to proteins and li ids, th  cell superna-
tant contains extracellular ve icl s t at can be isolated 
using an ultracentrifugation protocol, ultrafiltration, or 
immunoprecipitation technologies with antibody-tagged 
magnetic beads [111]. Extracellular vesicles are classi-
fied mainly based on the diameter, molecular weight, and 
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unknown. Oxidized phospholipids exert diverse biological 
functions in vitro and in vivo, suggesting that this class of 
lipids is responsible, at least in part, for the beneficial effect 
of cell secretome-based therapies.
Moving towards clinical application, physicians, non-
clinical researchers, and investors have collaborations 
with reciprocal advantages for each discipline. Clinically 
oriented researchers and non-clinical scientists are cur-
rently in fast-moving environments that provide great 
opportunities for both the development and implemen-
tation of novel therapeutic modalities [116]. However, 
the biologically active compo ents in th  cell secretome
and the mode of action (MOA) of these forms of therapy. 
For example, exosomes are currently n ntensiv ly inves-
tigated component of the cell secretome. Future resea ch 
should focus on a detailed descrip ion of the composition 
of exosomes, including exosomal lipids, mRNAs, miRNAs, 
proteins, and surface receptors. W  should try to und rstand 
the biological distribution of systemically injected paracrine 
factors to further characterize their organ-specific function.
In addition, whether apopt sis-induced lipid release has 
any beneficial effect in regenerative medicine is currently 
Fig. 2 Components, mode 
of action, and indication of 
paracrine factor-based therapies. 
The cell secretome consists of 
multiple paracrine factors that 
can be categorized into different 
biological classes. The best 
investigated components are 
proteins, lipids, and exosomes, 
which have been shown to 
exhibit in vitro and in vivo 
biological activity. Due to the 
complexity of paracrine factors 
present in the cell secretome, it 
is likely that other factors exert 
biological activity. Paracrine 
factors derived from apoptotic 
PBMCs have been shown 
to induce angiogenesis and 
vasodilation, exert antimicro-
bial activity, enhance re-
epithelialization, inhibit platelet 
coagulation, induce M1–M2 
polarization, augment the 
release of neurotropic factors, 
exhibit cytoprotective capaci-
ties due to the up-regulation of 
anti-apoptotic proteins, and act 
in an immunomodulatory man-
ner. Based on these biological 
effects, the PBMC secretome 
has been successfully tested in 
animal models to treat acute 
myocardial infarction, chronic 
heart failure, myocarditis, skin 
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should be completed successfully before venturing into 
the clinic.
In particular, knowledge of the MOA of a substance helps 
with regulatory approval. However, based on our experi-
ence in cell-based and paracrine research, a simplification 
of the monocausal effect of pleiotropic paracrine factors is 
considered absurd. Cell-free and cell-based therapies have 
multiple different molecular targets, and it is thought that 
only the interactions of these different effects lead to the 
beneficial clinical impacts observed in multiple pre-clinical 
studies.
Thus, a closer interaction between blood banks that know 
all of these regulatory issues with major pre-clinical driving 
forces could accelerate scientific progress.
Blood bank and transfusion units should not just fol-
low urgent changes in clinical settings, but be actively 
closer cooperation between the disciplines is needed to 
transform basic science in o clinical applicability that is 
in line with GMP guidelines a d regulato y c nstraints. 
For example, most clinically ori nted scientists do not 
know that the regulators differentiate between so-called 
advanced therapy medicinal products (ATMP ) and “bio-
logics” (Fig. 3). Paracrine-based therap es belong to the 
latter and are subjected to specialized gulatory restric-
tions if used in clinics. In Fig. 3, the d ffere t s ep-by-
step regulatory requirements for the approval of ell-free 
therapies are depicted star ing from extensive pre-clinical 
research via identification of the MOA to toxicological 
studies, stability assays, potency a says, and viral clear-
ance steps, eventually resulting in clinical testing in phase 
I and II studies. All of these manuf cturing and regula-
tory steps, including ethics approval and trial reg str tion, 
Fig. 3 Regulatory issues for cell-free therapies. To enable regulatory 
approval for testing paracrine factor-based therapy, several regulatory 
issues have to be fulfilled. First, cell-free therapies have to be dis-
criminated from cell-based medicinal products (ATMP). ATMPs deal 
with living cells, whereas paracrine factor-based therapies, such as 
APOSEC ™, contain only factors produced by living cells. In cell thera-
pies, the mode of action is thought to be mediated by the cells or their 
paracrine factors, whereas in cell-free therapies multiple paracrine 
fac ors are thought to ex rt the biological activity. The starting mate-
rial in both ie  are cells of human origin, either autologous or 
allogeneic. An important difference between these two types of thera-
p es is that viral clearance is not possible in ATMPs, but viral clearance 
steps c n be applied in cell-free therapies such as APOSEC™. In th
right si e of the figure, the different regu atory steps that have to be 
performed during the development of a cell-free therapy are depicted, 





The use of human PBMCs as bioreactors for secretome-
based therapies can be seen as an extension of the origi-
nal concept of stem cell-based therapies to enable clinical 
applications. A large number of studies of transplanted stem 
cells have failed to show any significant integration and dif-
ferentiation of injected cells into mature (cardiac) cells. In 
addition, there is a considerable loss of injected cells imme-
diately after translation. Using apoptotic PBMC-S instead of 
stem cells, we could promote tissue repair and regeneration 
in multiple pre-clinical indications with the identification of 
a variety of MOAs. However, as stem cells are rare, their 
isolation and cultivation in large numbers is neither simple 
nor practical. Therefore, a more easily obtainable source of 
cells as the “bioreactor” for the secretome may facilitate the 
introduction of this new secretome-based medicine.
PBMCs release pleiotropic paracrine factors that aug-
ment tissue regeneration, and their usage has the following 
incorporated into the process because they are familiar with 
GMP policy; they are familiar with handling inspections and 
experienced in testing biological samples [116]. Detail d 
knowledge of the risk involved with transfusion and trans-
plantation, as well as avoiding mi robial contamination, is 
crucial in setting up cell-free therapies, but these regula-
tions are not well known by medical profess onals except 
transfusion physicians. Blood banks could establish and 
run a cell-free therapy unit according to GMP. Thus, in the 
future, cooperation between clinic lly orie tated scientists 
and blood banks could accelerate the inclusion of inv s or , 
as the certification of a validated GMP facility would result 
in significant (financial) risk reduction. This will eventually 
introduce a novel chapter n the evolution of regenerative 
medicine, from cell-based therapies to cell-free therapies, 
from stem cell therapy to white blood cell th rapy, and from 
limited source therapy (e.g., stem ells) to an easily obtain-
able cell source, such as PBMCs, which r  a current waste 
product in transfusion units.
Fig. 4 Ethical, economic, and safety considerations of stem cell-based 
and paracrine factor-based therapies. In contrast to stem cell-based 
therapies, paracrine factor-based therapies can be seen as an economic, 
ethical, and fully acceptable therapeutic strategy lacking significant 
safety issues and restrictions in production capacity. Viral clearance 
methods are not possible in stem cell-based therapies containing myo-
blasts, bone marrow stem cells (BM-SCs), peripheral blood stem cells 
(PB-SCs), adipose tissue-derived stem cells (AT-SCs), mesenchymal 
stem cells (MSCs), cardiac stem cells (Cardiac-SCs), embryonic stem 
cells (ESCs), and induced pluripotent stem cells (iPSCs). In addition, 
ESC- an  iPSC-ba ed therapies are associated with high costs for 
cell manufacturing and low  numbers. Stem cell-based therapies 
with ESCs, and especially iPSCs, als  have ethical and safety con-
cerns because these cells have on embryonic source or bear a risk of 
malignant transforma ion. In contrast, paracrine factors derived from 
PBMCs or MSCs, including exosomes, proteins, and lipids, can be 
subject d to viral clearance methods, guaranteeing a viral-free medical 
drug. In addition paracrine factors, especially from peripheral blood 
mononuclear cells (PBMCs), can b  produced and stored in high 
amounts with ow costs
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advantages (Fig. 3): (I) PBMCs are a current waste prod-
uct from each red blood donation, so their amount is unre-
stricted compared to any stem cell population used thus 
far; (II) PBMCs are obtained from mainly heal hy persons, 
avoiding any disease- or age-dependent isadvantage in 
the PBMC secretome; (III) allogeneic samples with pooled 
PBMC factor from many individuals ca  be used inste d of 
a strict autologous stem cell therapy a proach; nd (IV) the 
use of PBMCs does not comprise significant ethical prob-
lems, unlike the use of fetal stem cells (Fig. 4).
In conclusion, the PBMC secretome may potentially rev-
olutionize regenerative medicine when appropriat  proof 
of concept studies in humans that meet the requirements of 
regulating agencies are finished.
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